Cargando…

Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy

Several patient-related factors that influence adherence to antiretroviral therapy (ART) have been described. However, studies that propose a practical and simple tool to predict nonadherence after ART initiation are still scarce. In this study, we develop and validate a score to predict the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Acin, Pablo, Luque, Sonia, Subirana, Isaac, Vila, Joan, Fernández-Sala, Xènia, Guelar, Ana, de Antonio-Cuscó, Marta, Arrieta, Itziar, Knobel, Hernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561744/
https://www.ncbi.nlm.nih.gov/pubmed/37294209
http://dx.doi.org/10.1089/aid.2022.0147
_version_ 1785117986882846720
author Acin, Pablo
Luque, Sonia
Subirana, Isaac
Vila, Joan
Fernández-Sala, Xènia
Guelar, Ana
de Antonio-Cuscó, Marta
Arrieta, Itziar
Knobel, Hernando
author_facet Acin, Pablo
Luque, Sonia
Subirana, Isaac
Vila, Joan
Fernández-Sala, Xènia
Guelar, Ana
de Antonio-Cuscó, Marta
Arrieta, Itziar
Knobel, Hernando
author_sort Acin, Pablo
collection PubMed
description Several patient-related factors that influence adherence to antiretroviral therapy (ART) have been described. However, studies that propose a practical and simple tool to predict nonadherence after ART initiation are still scarce. In this study, we develop and validate a score to predict the risk of nonadherence in people starting ART. The model/score was developed and validated using a cohort of people living with HIV starting ART at the Hospital del Mar, Barcelona, between 2012 and 2015 (derivation cohort) and between 2016 and 2018 (validation cohort),. Adherence was evaluated every 2 months using both pharmacy refills and patient self-reports. Nonadherence was defined as taking <90% of the prescribed dose and/or ART interruption for more than 1 week. Predictive factors for nonadherence were identified by logistic regression. Beta coefficients were used to develop a predictive score. Optimal cutoffs were identified using the bootstrapping methodology, and performance was evaluated with the C statistic. Our study is based on 574 patients: 349 in the derivation cohort and 225 in the validation cohort. A total of 104 patients (29.8%) of the derivation cohort were nonadherent. Nonadherence predictors were patient prejudgment; previous medical appointment failures; cultural and/or idiomatic barriers; heavy alcohol use; substance abuse; unstable housing; and severe mental illness. The cutoff point (receiver operating characteristic curve) for nonadherence was 26.3 (sensitivity 0.87 and specificity 0.86). The C statistic (95% confidence interval) was 0.91 (0.87–0.94). These results were consistent with those predicted by the score in the validation cohort. This easy-to-use, highly sensitive, and specific tool could be easily used to identify patients at highest risk for nonadherence, thus allowing resource optimization and achieving optimal treatment goals.
format Online
Article
Text
id pubmed-10561744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-105617442023-10-10 Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy Acin, Pablo Luque, Sonia Subirana, Isaac Vila, Joan Fernández-Sala, Xènia Guelar, Ana de Antonio-Cuscó, Marta Arrieta, Itziar Knobel, Hernando AIDS Res Hum Retroviruses Sociobehavioral Several patient-related factors that influence adherence to antiretroviral therapy (ART) have been described. However, studies that propose a practical and simple tool to predict nonadherence after ART initiation are still scarce. In this study, we develop and validate a score to predict the risk of nonadherence in people starting ART. The model/score was developed and validated using a cohort of people living with HIV starting ART at the Hospital del Mar, Barcelona, between 2012 and 2015 (derivation cohort) and between 2016 and 2018 (validation cohort),. Adherence was evaluated every 2 months using both pharmacy refills and patient self-reports. Nonadherence was defined as taking <90% of the prescribed dose and/or ART interruption for more than 1 week. Predictive factors for nonadherence were identified by logistic regression. Beta coefficients were used to develop a predictive score. Optimal cutoffs were identified using the bootstrapping methodology, and performance was evaluated with the C statistic. Our study is based on 574 patients: 349 in the derivation cohort and 225 in the validation cohort. A total of 104 patients (29.8%) of the derivation cohort were nonadherent. Nonadherence predictors were patient prejudgment; previous medical appointment failures; cultural and/or idiomatic barriers; heavy alcohol use; substance abuse; unstable housing; and severe mental illness. The cutoff point (receiver operating characteristic curve) for nonadherence was 26.3 (sensitivity 0.87 and specificity 0.86). The C statistic (95% confidence interval) was 0.91 (0.87–0.94). These results were consistent with those predicted by the score in the validation cohort. This easy-to-use, highly sensitive, and specific tool could be easily used to identify patients at highest risk for nonadherence, thus allowing resource optimization and achieving optimal treatment goals. Mary Ann Liebert, Inc., publishers 2023-10-01 2023-10-03 /pmc/articles/PMC10561744/ /pubmed/37294209 http://dx.doi.org/10.1089/aid.2022.0147 Text en © Pablo Acin et al. 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sociobehavioral
Acin, Pablo
Luque, Sonia
Subirana, Isaac
Vila, Joan
Fernández-Sala, Xènia
Guelar, Ana
de Antonio-Cuscó, Marta
Arrieta, Itziar
Knobel, Hernando
Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title_full Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title_fullStr Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title_full_unstemmed Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title_short Development and Validation of a Risk Score for Predicting Non-Adherence to Antiretroviral Therapy
title_sort development and validation of a risk score for predicting non-adherence to antiretroviral therapy
topic Sociobehavioral
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561744/
https://www.ncbi.nlm.nih.gov/pubmed/37294209
http://dx.doi.org/10.1089/aid.2022.0147
work_keys_str_mv AT acinpablo developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT luquesonia developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT subiranaisaac developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT vilajoan developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT fernandezsalaxenia developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT guelarana developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT deantoniocuscomarta developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT arrietaitziar developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy
AT knobelhernando developmentandvalidationofariskscoreforpredictingnonadherencetoantiretroviraltherapy